Banna GL - Search Results

1

A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial.

Banna GL, Addeo A, Zygoura P, Tsourti Z, Popat S, Curioni-Fontecedro A, Nadal E, Shah R, Pope A, Fisher P, Spicer J, Roy A, Gilligan D, Gautschi O, Janthur WD, López-Castro R, Roschitzki-Voser H, Dafni U, Peters S, Stahel RA. Banna GL, et al. Lung Cancer. 2022 Jul;169:77-83. doi: 10.1016/j.lungcan.2022.05.018. Epub 2022 May 28. Lung Cancer. 2022. PMID: 35660972 Clinical Trial.

2

Adding an invasive procedure will not necessarily change treatment or outcome of NSCLC patients with preoperative clinical N1 disease.

Addeo A, Banna G. Addeo A, et al. Eur Respir J. 2018 Apr 4;51(4):1800084. doi: 10.1183/13993003.00084-2018. Print 2018 Apr. Eur Respir J. 2018. PMID: 29618603 Free article. No abstract available.

3

Oral Metronomic Vinorelbine in Advanced Non-small Cell Lung Cancer Patients Unfit for Chemotherapy.

Banna GL, Camerini A, Bronte G, Anile G, Addeo A, Rundo F, Zanghì G, Lal R, Libra M. Banna GL, et al. Anticancer Res. 2018 Jun;38(6):3689-3697. doi: 10.21873/anticanres.12647. Anticancer Res. 2018. PMID: 29848729 Clinical Trial.

4

Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients' selection.

Banna GL, Passiglia F, Colonese F, Canova S, Menis J, Addeo A, Russo A, Cortinovis DL. Banna GL, et al. Crit Rev Oncol Hematol. 2018 Sep;129:27-39. doi: 10.1016/j.critrevonc.2018.06.016. Epub 2018 Jun 23. Crit Rev Oncol Hematol. 2018. PMID: 30097235 Review.

5

The crucial role of predicting brain metastases development in non-small cell lung cancer patients.

Addeo A, Banna GL. Addeo A, et al. Among authors: banna gl. J Thorac Dis. 2018 Sep;10(Suppl 26):S3305-S3307. doi: 10.21037/jtd.2018.08.95. J Thorac Dis. 2018. PMID: 30370144 Free PMC article. No abstract available.

6

PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

Addeo A, Banna GL. Addeo A, et al. Among authors: banna gl. Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S283-S286. doi: 10.21037/tlcr.2018.07.10. Transl Lung Cancer Res. 2018. PMID: 30393623 Free PMC article. No abstract available.

7

PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

Addeo A, Banna GL. Addeo A, et al. Among authors: banna gl. Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S287-S289. doi: 10.21037/tlcr.2018.07.09. Transl Lung Cancer Res. 2018. PMID: 30393624 Free PMC article. No abstract available.

8

Learning from the past to design better trials in second-line treatment for mesothelioma patients.

Addeo A, Banna GL, Dietrich PY. Addeo A, et al. Among authors: banna gl. Ecancermedicalscience. 2018 Nov 12;12:881. doi: 10.3332/ecancer.2018.881. eCollection 2018. Ecancermedicalscience. 2018. PMID: 30679948 Free PMC article.

9

Next Generation Sequencing and Genetic Alterations in Squamous Cell Lung Carcinoma: Where Are We Today?

Friedlaender A, Banna G, Malapelle U, Pisapia P, Addeo A. Friedlaender A, et al. Front Oncol. 2019 Mar 19;9:166. doi: 10.3389/fonc.2019.00166. eCollection 2019. Front Oncol. 2019. PMID: 30941314 Free PMC article. Review.

10

Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis.

Addeo A, Banna GL, Metro G, Di Maio M. Addeo A, et al. Among authors: banna gl. Front Oncol. 2019 Apr 16;9:264. doi: 10.3389/fonc.2019.00264. eCollection 2019. Front Oncol. 2019. PMID: 31058078 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

218 results

Search Page

Filters